Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Seo, Yu Ri | - |
dc.contributor.author | Kim, Se Hyung | - |
dc.contributor.author | Kim, Hyun Jung | - |
dc.contributor.author | Kim, Chan Kyu | - |
dc.contributor.author | Park, Seong Kyu | - |
dc.contributor.author | Koh, Eun Suk | - |
dc.contributor.author | Hong, Dae Sik | - |
dc.date.accessioned | 2021-08-12T07:25:05Z | - |
dc.date.available | 2021-08-12T07:25:05Z | - |
dc.date.issued | 2010-01-20 | - |
dc.identifier.issn | 1756-8722 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/18064 | - |
dc.description.abstract | No standard has been established for salvage therapy in gemcitabine refractory advanced urothelial cancer. We report the complete response to FOLFOX4 therapy of a metastatic urothelial cancer patient, for whom adjuvant gemcitabine plus cisplatin combination chemotherapy had failed. A 54-year-old male patient with urothelial cancer (transitional cell carcinoma) in the right kidney underwent three rounds of adjuvant gemcitabine-cisplatin chemotherapy after extensive radical nephrectomy. However, he had new liver, lung metastases and synchronous two separate primary colon cancer. The lung metastasis lesion was confirmed as a metastatic urothelial cancer via percutaneous transthoracic needle biopsy (PTNB). Liver and lung metastasis lesions disappeared after the 4th cycle of FOLFOX4 chemotherapy. In addition, colon cancer also disappeared after the 8th cycle of FOLFOX4 chemotherapy. The patient was still showing a complete response after 4 months. Clinical trials using the FOLFOX regimen as salvage therapy for gemcitabine-refractory advanced urothelial cancer are warranted. | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | BioMed Central | - |
dc.title | Complete response to FOLFOX4 therapy in a patient with advanced urothelial cancer: a case report | - |
dc.type | Article | - |
dc.publisher.location | 영국 | - |
dc.identifier.doi | 10.1186/1756-8722-3-4 | - |
dc.identifier.scopusid | 2-s2.0-76749137280 | - |
dc.identifier.wosid | 000274825900001 | - |
dc.identifier.bibliographicCitation | Journal of Hematology and Oncology, v.3 | - |
dc.citation.title | Journal of Hematology and Oncology | - |
dc.citation.volume | 3 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | TRANSITIONAL-CELL-CARCINOMA | - |
dc.subject.keywordPlus | URINARY-TRACT | - |
dc.subject.keywordPlus | PHASE-II | - |
dc.subject.keywordPlus | FLUOROURACIL-LEUCOVORIN | - |
dc.subject.keywordPlus | PROGNOSTIC-FACTORS | - |
dc.subject.keywordPlus | OXALIPLATIN | - |
dc.subject.keywordPlus | CISPLATIN | - |
dc.subject.keywordPlus | CHEMOTHERAPY | - |
dc.subject.keywordPlus | METHOTREXATE | - |
dc.subject.keywordPlus | VINBLASTINE | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.